Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Control Release ; 351: 727-738, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36162554

ABSTRACT

The cluster of differentiation 47 (CD47) protein is abundantly expressed on various malignant cells and suppresses the phagocytic function of macrophages and dendritic cells. High CD47 expression levels are correlated with poor cancer survival. Antagonizing CD47 antibodies with potent antitumor effects have been developed in clinical trials, but have critical side effects, inducing anemia and thrombocytopenia. To develop a safe and potent CD47 blockade, we designed extracellular vesicles (EVs) harboring signal regulatory protein alpha (SIPRα)-EV-SIRPα (EVs that express SIPRα). EV-SIRPα showed minimal toxic effects on hematologic parameters and utilized RBCs as delivery vehicles to tumors rather than inducing anemia. EV-SIRPα inhibited ligation of residual CD47 molecules, which attribute to the EV-endocytosis-mediated CD47 depletion and steric hindrance of EV. In an immunologically cold tumor model, EV-SIRPα induced tumor-specific T-cell-mediated antitumor effects. When directly administered to the accessible lesions, EV-SIRPα monotherapy elicited an abscopal effect in the B16F10 tumor model by increasing immune cell infiltration and CD8+-mediated immunity against non-treated tumors. The combinational approach by loading doxorubicin into the EV-SIRPα dramatically reduced the tumor burden and led to 80% complete remission rate. Thus, a potent EV-based CD47 blockade that is hematologically safe, has efficient signaling blocking efficacy, and has systemic antitumor immunity against cancer is recommended.


Subject(s)
Extracellular Vesicles , Neoplasms , Humans , CD47 Antigen , Immunotherapy , Antigens, Differentiation/metabolism , Neoplasms/drug therapy , Neoplasms/metabolism , Macrophages , Extracellular Vesicles/metabolism , Phagocytosis
2.
Nat Commun ; 9(1): 2777, 2018 07 17.
Article in English | MEDLINE | ID: mdl-30018371

ABSTRACT

Cas12a (also called Cpf1) is a representative type V-A CRISPR effector RNA-guided DNA endonuclease, which provides an alternative to type II CRISPR-Cas9 for genome editing. Previous studies have revealed that Cas12a has unique features distinct from Cas9, but the detailed mechanisms of target searching and DNA cleavage by Cas12a are still unclear. Here, we directly observe this entire process by using single-molecule fluorescence assays to study Cas12a from Acidaminococcus sp. (AsCas12a). We determine that AsCas12a ribonucleoproteins search for their on-target site by a one-dimensional diffusion along elongated DNA molecules and induce cleavage in the two DNA strands in a well-defined order, beginning with the non-target strand. Furthermore, the protospacer-adjacent motif (PAM) for AsCas12a makes only a limited contribution of DNA unwinding during R-loop formation and shows a negligible role in the process of DNA cleavage, in contrast to the Cas9 PAM.


Subject(s)
Acidaminococcus/genetics , CRISPR-Associated Protein 9/genetics , CRISPR-Cas Systems , DNA/genetics , RNA, Guide, Kinetoplastida/genetics , Acidaminococcus/enzymology , Base Pairing , Base Sequence , CRISPR-Associated Protein 9/metabolism , Cloning, Molecular , DNA/metabolism , DNA Cleavage , Escherichia coli/enzymology , Escherichia coli/genetics , Gene Editing , Gene Expression , Genetic Vectors/chemistry , Genetic Vectors/metabolism , Isoenzymes/genetics , Isoenzymes/metabolism , Models, Molecular , Nucleic Acid Conformation , Nucleic Acid Heteroduplexes , RNA, Guide, Kinetoplastida/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...